Precision medicine software company GenomOncology on Monday announced a collaboration with Chronetyx Laboratories, a provider of advanced diagnostic solutions, to accelerate cancer care through comprehensive genomic profiling.

The partnership is intended to significantly reduce turnaround times for next-generation sequencing (NGS) testing results and streamline cancer care delivery. It integrates GenomOncology's Pathology Workbench with Chronetyx Laboratories' NGS and information systems, specifically supporting the FDA-cleared and CE-IVD-Marked Cyx Solid Tumor 505 test, enabling healthcare providers to receive critical genomic insights faster and make more timely treatment decisions.

This combination is intended to address a critical challenge in precision medicine: the time gap between sample collection and actionable results. By implementing GenomOncology's Pathology Workbench as the tertiary analysis and clinical genomic reporting platform, Chronetyx Laboratories reduced result delivery times by eliminating manual processes and automating complex genomic interpretations.